<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211782</url>
  </required_header>
  <id_info>
    <org_study_id>AC-10-006</org_study_id>
    <nct_id>NCT01211782</nct_id>
  </id_info>
  <brief_title>AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)</brief_title>
  <acronym>ALERT</acronym>
  <official_title>A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accera, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety &amp; efficacy of AC-1204, a ketogenic compound, administered
      orally on a daily basis for 6 months. Following the 6 month double-blind phase of the study,
      subjects may enroll in an optional 6 month open-label extension phase. Efficacy will be
      evaluated by standard tests of memory and cognition, along with other measurements of
      activities of daily living and quality of life. Safety will be assessed by frequency of
      adverse events and changes in laboratory test results. Subjects will be stratified and
      outcomes will be separately analyzed based on apolipoprotein E4 genotype (APOE4).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two primary outcome measures will be assessed in APOE4(-) patients:

        1. differences from baseline between AC-1204 and placebo groups' ADAS-cog scores at 6
           months

        2. differences from baseline between AC-1204 and placebo groups' CIBIC+ scores at 6 months
           Secondary endpoints will include differences between AC-1204 &amp; placebo groups' scores
           for these same instruments at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never started. Study was redesgined.
  </why_stopped>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's disease assessment scale - cognitive subscale (ADAS-cog)</measure>
    <time_frame>6 months</time_frame>
    <description>change from baseline in ADAS-cog scores at 6 months in APOE4(-) patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinicians Interview Based Impression of Change with Caregiver Input (CIBIC+)</measure>
    <time_frame>6 months</time_frame>
    <description>change from baseline in CIBIC+ scores at 6 months in APOE4(-) patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AC-1204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caprylic triglyceride</intervention_name>
    <description>oral, 20 gm, daily x 6 months</description>
    <arm_group_label>AC-1204</arm_group_label>
    <other_name>AC-1204</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long-chain triglyceride</intervention_name>
    <description>oral, 14 gm, daily x 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sunflower oil + maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males/females between age of 55 -85 years

          -  MMSE scores between 16-26

          -  Probable mild to moderate AD

        Exclusion Criteria:

          -  Presence of other CNS disorders as alternative causes of dementia

          -  Type 1 or Type 2 diabetes

          -  Significant renal/hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mildred Farmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meridien Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>AD</keyword>
  <keyword>AC-1204</keyword>
  <keyword>ketogenic</keyword>
  <keyword>ketosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

